RushNet, Inc.

RushNet, Inc.

RSHN
RushNet, Inc.US flagOther OTC
0.00
USD
- -
- -
857,642.00Market Cap
No data availableFinancial data will appear here once available

Capital Structure

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Revenue

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Company Description

APIChat
CEO
Michael A. Cunha
Full Time Employees
17
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Address
12201 S Western Avenue Blue Island IL United States of America 60406
IPO Date
Oct 20, 1998
Business
RushNet, Inc. (OTC Pink: RSHN) operates as a healthcare services company focused on laboratory diagnostic testing, management, and insurance billing, primarily through its subsidiary heliosDX, a national clinical reference laboratory, and Grandeza Healthcare, a billing and coding firm; core offerings encompass high-complexity urine drug testing, behavioral drug testing, allergy droplet cards, oral fluids testing, PCR panels for nail, wound, respiratory pathogen, STI, GI, and UTI conditions via lab partners, infectious disease services, and patient-centered billing protocols with in-house processing and easy online payments. The company, founded in 1997 and headquartered at 8465 Merchants Way, Suite 206, Jacksonville, Florida, serves physicians and patients across the United States with prompt 48-hour resulting, interactive sales and results portals, and streamlined shipping via Cardinal Health partnerships. Recent developments include debt restructuring to resume partner payments at 3% of monthly gross revenues with 1% interest, appointment of Michael A. Cunha as CEO and Chairman in 2024, a 79% reduction in authorized and fully diluted outstanding shares, cancellation of a proposed reverse split, and pursuit of revenue growth targets aiming for $50 million in three years amid expansions into blood toxicology, hormone testing, and wellness patches for retail via Amazon and its website.

Company News

APIChat
  • RushNet Licensing Partner Royal Caridea Achieves the Fastest Shrimp Growth Rate in the Aquaculture Industry Reaching 42 Grams in 90 Days

  • RushNet Partners with Royal Caridea LLC Through an Exclusive Licensing Agreement to Revolutionize Sustainable Aquaculture

  • RushNet Names Arizona Businessman Michael Cunha as Chairman and Chief Executive Officer

  • RushNet Announces: A New Era for Digital Community Engagement

  • heliosDX Succumbs to Unprecedented Challenges in the Healthcare Market

  • heliosDX to Present at the Emerging Growth Conference on Wednesday October 27, 2021; Invites Institutional and Individual Investors

  • RushNet, Inc (RSHN) Subsidiary heliosDX Surpasses Major Financial Milestone, on Track with 2021 Stretch Target of $6 Million in Revenue

  • heliosDX to Remain as a Rushnet Subsidiary Along With Grandeza Healthcare

  • heliosDX Adds Artificial Intelligence to its Suite of Diagnostics Services and Solutions

  • heliosDX Announces Pursuit of TSX-V Listing and Roadmap Update

  • heliosDX Announces Director of Sales and Marketing

  • RushNet, Inc and heliosDX Announces Appointment of COO

  • heliosDX Announces First Board Member upon Split-Off of RushNet, Inc and RushNet Share Conversion

  • RushNet, Inc Closes the Acquisition of heliosDX which Brings Significant Revenues to the Company

  • RushNet, Inc with heliosDX Announces Roadmap Update, Dividend Enhancements, and Acquisition Update

  • RushNet Inc. to Close on Acquisition/Spinoff of HeliosDX and Reveals Future Plans

  • RushNet Inc. Cancellation of Proposed Reverse Split

  • heliosDX and RushNet Inc. Sign Binding Letter of Intent to Acquire Laboratory and Target Additional Laboratory Acquisitions

  • RushNet, Inc Reverse Merger and Roadmap Update